Clinical trials: Obesity and Cardiovascular Risk
Obesity
Virtual Lifestyle Management: Prevention Through the UPMC Patient Portal
Diabetes affects 18 million Americans and costs over $132 billion in both direct treatment and lost productivity per year. It is known that weight loss, improved diet and increased exercise can result in improvement in glucose…
- Trial name
- NCT00409786
- Testing
- Virtual Lifestyle Management (VLM)
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- University of Pittsburgh
Obesity, Overweight
Method-of-Use Study Assessing the Effect of Naltrexone Sustained Release (SR)/ Bupropion SR on Body Weight and Cardiovascular Risk Factors in Overweight and Obese Subjects
The purpose of this Phase 3b study is to assess the effects of combination therapy with naltrexone SR/bupropion SR (NB) used in conjunction with a comprehensive lifestyle intervention (CLI) and in a manner consistent with its…
- Trial name
- NCT01764386
- Testing
- NB, CLI, Usual Care
- Where
- 15 sites in United States
- Volunteers
- 242 people
- Sponsor
- Orexigen Therapeutics, Inc
Obesity, Cardiovascular Risk Factor
The Pitt Retiree Study: A Diabetes Prevention Program for Medicare Eligible Older Adults
The Pitt Retiree Study (PRS) disseminates a novel, yet practical, diabetes prevention program among Medicare eligible adults in Western Pennsylvania.
- Conditions
- Obesity, Cardiovascular Risk Factor, Eating Behavior, Diet Modification
- Trial name
- PRS (NCT03192475)
- Testing
- GLB plus phone contacts, GLB plus newsletter contacts
- Volunteers
- 322 people, healthy volunteers welcome
- Sponsor
- University of Pittsburgh
Systemic Hypertension, Obesity
GAstric Bypass to Treat obEse Patients With steAdy hYpertension
Phase 3, unicentric, randomized clinical trial, with allocation concealment and intention-to-treat analysis to evaluate the efficacy of videolaparoscopic Roux-en-Y Gastroplasty to decrease the prescription of antihypertensive…
- Trial name
- GATEWAY (NCT01784848)
- Testing
- Laparoscopic Roux-en-Y gastric bypass (LRYGB), Clinical treatment
- Where
- 3 sites in Brazil
- Volunteers
- 100 people
- Sponsor
- Hospital do Coracao
Obesity
Growth Hormone, Cardiovascular Risk, and Visceral Adiposity
This study will compare growth hormone levels and cardiovascular risk markers in normal weight and overweight women and men. In women and men with increased abdominal weight, growth hormone (GH) versus placebo will be…
- Trial name
- NCT00131378
- Testing
- Nutropin AQ growth hormone
- Where
- United States
- Volunteers
- 142 people, healthy volunteers welcome
- Sponsor
- Massachusetts General Hospital
Obesity, Overweight
Cardiovascular Outcomes Study of Naltrexone SR/Bupropion SR in Overweight and Obese Subjects With Cardiovascular Risk Factors (The Light Study)
The purpose of this study is to determine the effects of NB relative to placebo on major adverse cardiovascular events (MACE) such as cardiovascular death, non-fatal myocardial infarction, and non-fatal stroke in overweight and…
- Trial name
- NCT01601704
- Testing
- NB32, PBO, Weight Management Program
- Where
- 224 sites in United States
- Volunteers
- 8,910 people
- Sponsor
- Orexigen Therapeutics, Inc
Down Syndrome, Trisomy 21
Down Syndrome Metabolic Health Study
The purpose of this research study is to determine which measures best capture cardiovascular disease (CVD) risk and type 2 diabetes (T2DM) risk in children and adolescents with Down syndrome (DS).
- Trial name
- NCT01821300
- Where
- 2 sites in United States
- Volunteers
- 257 people, healthy volunteers welcome
- Sponsor
- Children's Hospital of Philadelphia
Cardiovascular-kidney-metabolic Syndrome, Cardiovascular Disease Risk Factor
Early Add-On Combination of GLP-1 Receptor Agonist and SGLT2 Inhibitor in People With Cardiovascular-Kidney-Metabolic Stage 2-3
This retrospective observational target-trial emulation uses electronic health record data from the TriNetX US Collaborative Network to compare early treatment intensification strategies in adults with obesity, type 2 diabetes…
- Conditions
- Cardiovascular-kidney-metabolic Syndrome, Cardiovascular Disease Risk Factor, Kidney Disease, Type 2 Diabetes
- Trial name
- GLP1-SGLT2-CKM (NCT07465926)
- Testing
- GLP-1 receptor agonist, SGLT2 inhibitor
- Volunteers
- 451,036 people
- Sponsor
- Chung Shan Medical University
Non-Alcoholic Fatty Liver Disease, Obesity
Growth Hormone Releasing Hormone Analog to Improve Nonalcoholic Fatty Liver Disease and Associated Cardiovascular Risk
Nonalcoholic fatty liver disease (NAFLD) is common in individuals with obesity and is a significant threat to public health, because it can lead to impaired liver function and liver failure.
- Conditions
- Non-Alcoholic Fatty Liver Disease, Obesity, Obesity, Abdominal, Liver Fat
- Trial name
- NCT03375788
- Testing
- Tesamorelin
- Where
- United States
- Volunteers
- 51 people
- Sponsor
- Massachusetts General Hospital
Pre-Eclampsia, Hypertension in Pregnancy
Effectiveness of Higher Aspirin Dosing for Prevention of Preeclampsia in High Risk Obese Gravida
To compare the incidence of preeclampsia in obese pregnant women (BMI greater than 30) with a singleton gestation at less than 20 weeks and either a history of preeclampsia in a prior pregnancy or stage I hypertension or…
- Conditions
- Pre-Eclampsia, Hypertension in Pregnancy, Obesity
- Trial name
- ASPREO (NCT03961360)
- Testing
- Aspirin 81 mg, Aspirin 162 mg
- Where
- United States
- Volunteers
- 220 people
- Sponsor
- The University of Texas Health Science Center, Houston
Obesity, Cardiovascular Disease
Effectiveness of Four Popular Diet Strategies for Weight Loss and Cardiac Risk Reduction
A single-center randomized trial at an academic medical center in Boston, Mass, of overweight or obese adults with known hypertension, dyslipidemia, or fasting hyperglycemia.
- Conditions
- Obesity, Cardiovascular Disease, Metabolic Syndrome
- Trial name
- NCT02454127
- Testing
- Atkins Diet, Zone Diet, Weight Watchers Diet
- Volunteers
- 160 people
- Sponsor
- Tufts Medical Center
Cardiovascular Risk Factor, Cardiovascular Diseases
Effects of Breaking up Prolonged Sitting on Postprandial Cardiometabolic Disease Risk Markers in South Asian Adults
The purpose of this study is to examine whether breaking up prolonged sitting with short regular bouts of walking can reduce blood sugar and cholesterol levels after eating, which are risk markers for Type 2 diabetes and heart…
- Conditions
- Cardiovascular Risk Factor, Cardiovascular Diseases, Diabetes, Physical Activity
- Trial name
- NCT03898206
- Testing
- Breaking up sitting with walking breaks (INT-SIT), Prolonged sitting (SIT)
- Where
- United Kingdom
- Volunteers
- 54 people, healthy volunteers welcome
- Sponsor
- University of Bedfordshire